Covidien's medical devices division president on reviving the company after its spinout from Tyco Healthcare and how it turned around in a down economy.
José Almeida knows what it takes to succeed. The native of Brazil, a mechanical engineer by training, put down roots in the U.S. 20 years ago and never looked back.
Since then he's worked his way up the corporate ladder at firms including Acufex Microsurgical, Johnson & Johnson (NYSE:JNJ), Greatbatch Technologies and Tyco Healthcare. When the latter spun out into Covidien in late June, 2007, Almeida had been in his current role for a year already after spending the better part of 12 years with the company.
MassDevice spoke with...
Researchers Sanket Dhruva and Rita Redberg on the hornet's nest they stirred up with their study of the Food & Drug Administration's approval process for high-risk cardiovascular devices.
It's not often that a few doctors ensconced in the ivy towers of academia can get a lumbering dinosaur like the Food & Drug Administration to turn on a dime, let alone during the week between Christmas and the new year.
But that's exactly what University of California at San Francisco researchers Sanket S. Dhruva, Lisa Bero and Rita Redberg did after the Journal of the American Medical Assn. published their paper "Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices."
The study, which...
Robert Creeden, managing director of Partners Innovation Fund, on reviewing business plans and the state of innovation.
Robert Creeden knows a little something about how to invest in early-stage companies. A former vice president at the Massachusetts Technology Development Corp. and a general partner at Egan-Managed Capital, Creeden has spent countless hours on due diligence for new ventures.
But it's his current position, as one of the managing directors of the Partners Innovation Fund at Partners Healthcare that puts him in the catbird seat at one of the healthcare industries...
Serica Technologies Inc. president and CEO Greg Altman on leveraging a platform product and the importance of creating a "learning organization."
Thirteen years ago Greg Altman, president and CEO of Serica Technologies Inc., blew out his knee playing football. After reconstructive surgery on his ruptured anterior cruciate ligament, the former All-American at Tufts University found the rehabilitation process so challenging that he set out to develop an alternative.
That led to the 1998 founding of Tissue Regeneration Inc. (later renamed Serica), which sought to commercialize Altman's doctoral work in biomedical engineering. Although its initial focus on developing a tissue-engineered ligament from adult stem cells didn't pan out, the company was able to shift gears and examine the...
Advertising executive Bruce Lehman on the challenges and opportunities in marketing medical devices for the masses.
Bruce Lehman's been in the advertising game since the late 1970s, but the principal at Lehman Millet, a Boston-based marketing and communications agency, has been focused on the medical device and diagnostics industry solely since the 1990s, making it a powerful player in the industry despite its relatively small size.
Today, Lehman Millet's client mix includes biotechnology, biomaterials and specialty pharmaceutical firms, along with its core medical device customers. MassDevice: spoke with Lehman, 59, about an ever-present...
Thermo Fisher Scientific's new CEO Marc Casper on taking the reins from Marijn Dekkers and his cautious optimism about 2010.
To outside observers, Marijn Dekkers' departure from the corner office at Thermo Fisher Scientific (NYSE:TMO) might have seemed abrupt. After a seven-year run during which he led a profound re-shaping of the laboratory equipment and supplies manufacturer (and boosted revenues from the $2 billion range to about $10.5 billion a year), Dekkers resigned as CEO of the Waltham, Mass.-based firm to take the helm at German pharma giant Bayer AG.
But from the inside the move likely seemed a lot smoother, as Thermo Fisher tapped long-time COO Marc Casper to take Dekkers'...